We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, craniomaxillofacial and thoracic products (“CMFT”); office based technologies; dental implants; and related surgical products. Due to the 2019 Restructuring Plan that was initiated in late 2019, our operating segments have changed beginning in the first quarter of 2020. Our chief operating decision maker (“CODM”) now allocates resources to achieve our operating profit goals through three operating segments. These operating segments, which also constitute our reportable segments, are Americas and Global Businesses; EMEA; and Asia Pacific. Previously, we had seven operating segments, which resulted in three reportable segments and four individually insignificant operating segments that were aggregated together and not considered a reportable segment.

Our CODM evaluates performance based upon segment operating profit exclusive of operating expenses pertaining to inventory and manufacturing-related charges, intangible asset amortization, goodwill and intangible asset impairment, restructuring and other cost reduction initiatives, quality remediation, acquisition, integration and related, litigation, litigation settlement gain, certain European Union Medical Device Regulation expenses, other charges and corporate functions. Corporate functions include corporate legal, finance, information technology, human resources and other corporate departments. Intercompany transactions have been eliminated from segment operating profit.

Our Americas and Global Businesses operating segment is comprised principally of the U.S. and includes other North, Central and South American markets for all of our product categories as well as the global results for our Dental product category. This segment also includes our global manufacturing operations for all product categories and research, development engineering, medical education, and brand management for our global product category headquarter locations. Our EMEA operating segment is comprised principally of Europe and includes the Middle East and African markets for all product categories except Dental. Our Asia Pacific operating segment is comprised principally of Japan, China and Australia and includes other Asian and Pacific markets for all product categories except Dental. The EMEA and Asia Pacific operating segments include the commercial operations as well as regional headquarter expenses to operate in those markets.

Since the Americas and Global Businesses includes additional costs related to global manufacturing operations and other centralized global product category headquarter expenses, profitability metrics in this operating segment are not comparable to the EMEA and Asia Pacific operating segments.

Our CODM does not review asset information by operating segment. Instead, our CODM reviews cash flow and other financial ratios by operating segment.

Prior period reportable segment financial information has been reclassified to conform to our new reportable segments.

	Net Sales				Operating (Loss) Profit
	Three Months Ended				Three Months Ended
	June 30,				June 30,
	2020		2019		2020			2019
Americas and Global Businesses	$	757.5	$	1,255.1	$	83.0		$	427.2
EMEA		204.1		405.8		20.0			117.5
Asia Pacific		264.5		327.7		78.4			118.0
Corporate Functions		-		-		(111.6	)		(117.5	)
Total	$	1,226.1	$	1,988.6
Inventory and manufacturing-related charges						(1.4	)		(34.1	)
Intangible asset amortization						(147.7	)		(146.9	)
Intangible asset impairment						(33.0	)		(70.1	)
Restructuring and other cost reduction initiatives						(28.0	)		(6.9	)
Quality remediation						(9.9	)		(23.4	)
Acquisition, integration and related						(2.2	)		(5.1	)
Litigation						(1.3	)		(7.0	)
European Union Medical Device Regulation						(6.1	)		(5.1	)
Other charges						(11.9	)		(41.9	)
Operating (loss) profit					$	(171.7	)	$	204.7

	Net Sales				Operating (Loss) Profit
	Six Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020			2019
Americas and Global Businesses	$	1,894.1	$	2,490.7	$	451.8		$	817.2
EMEA		575.4		834.7		128.8			256.7
Asia Pacific		540.4		638.7		171.0			231.5
Corporate Functions		-		-		(215.6	)		(235.2	)
Total	$	3,009.9	$	3,964.1

Inventory and manufacturing-related charges						(2.0	)		(36.1	)
Intangible asset amortization						(295.3	)		(290.3	)
Goodwill and intangible asset impairment						(645.0	)		(70.1	)
Restructuring and other cost reduction initiatives						(73.0	)		(11.6	)
Quality remediation						(25.8	)		(43.1	)
Acquisition, integration and related						(6.6	)		(11.1	)
Litigation						(81.1	)		(5.2	)
Litigation settlement gain						-			23.5
European Union Medical Device Regulation						(17.1	)		(6.7	)
Other charges						(17.8	)		(64.6	)
Operating (loss) profit					$	(627.7	)	$	554.9